A ranked presentation of the MHRA/CSM (Medicines & Health Care Regulatory Agency/Committee on Safety of Medicines) Drug Analysis Print (DAP) data on protocol

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 10, 2005, Pages 705-710

  Mann, Ronald D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adverse reactions reporting; Drug analysis prints; Drug safety; Drug toxicity; Drugs withdrawn after marketing; Iatrogenic diseases; Methodology; Oculomucocutaneous syndrome; Practolol; Ranked data; Yellow card scheme

Indexed keywords

ALTHESIN; BENOXAPROFEN; CERIVASTATIN; CISAPRIDE; DEXFENFLURAMINE; DILEVALOL; FENCLOFENAC; FENFLURAMINE; FEPRAZONE; GREPAFLOXACIN; INDOMETACIN; INDOPROFEN; METIPRANOLOL; MIBEFRADIL; NOMIFENSINE MALEATE; PEMOLINE; PERHEXILINE MALEATE; PRACTOLOL; REMOXIPRIDE; ROFECOXIB; SERTINDOLE; SUPROFEN; TERODILINE; TOLCAPONE; TRIAZOLAM; TROGLITAZONE; UNINDEXED DRUG; VALDECOXIB; ZIMELDINE; ZOMEPIRAC;

ANAPHYLAXIS; APLASTIC ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG APPROVAL; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EYE DISEASE; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HUMAN; LICENCE; LIVER TOXICITY; MENTAL DISEASE; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RHABDOMYOLYSIS; SKIN MANIFESTATION; SMALL INTESTINE PERFORATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UVEITIS; VALVULAR HEART DISEASE;

ADRENERGIC BETA-ANTAGONISTS; ADVERSE DRUG REACTION REPORTING SYSTEMS; CONSUMER PRODUCT SAFETY; EYE DISEASES; GASTROINTESTINAL DISEASES; GREAT BRITAIN; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PRACTOLOL; SKIN DISEASES; SYNDROME;

EID: 27144451244     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1144     Document Type: Article

References (8)

1. Mann RD. Modern Drug Use. MTP Press: Lancaster, UK, 1984; 617.
2. Mann RD. The ethos of drug safety monitoring. Br Med J 1998; 316: 837.
3. Mann RD. Monitoring the safety of medicines. In Clinical Research Manual, Luscombe D, Stonier P (eds). Euromed Communications: Haslemere, UK, 1985; 8.42.
4. Brown EG. Dictionaries and Coding in Pharmacovigilance. In Stephens' Detection of New Adverse Drug Reactions, (5th edn), Talbot J, Waller P (eds). Wiley: Chichester UK, 2004; 533-556.
5. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: Observational study. Br Med J 1998; 317: 119-120.
6. Heeley E, Riley J, Layton D, Wilton LV, Shakir SAW. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 356: 1872-1873.
7. Anon. Current Problems, Number 4. Committee on Safety of Medicines, London, England, 1979; 1.
8. Nicholls JT. The practolol syndrome - a retrospective analysis. In Post-Marketing Surveillance of Adverse Reactions to New Medicines. Medico-Pharmaceutical Forum: London, England, 1978; 4-11.